HOME >> BIOLOGY >> NEWS
Host response to anthrax lethal toxin suggests some current treatment strategies are inappropriate

Anthrax, a disease previously primarily relevant to the livestock-management community recently became a wordwide bioterrorism concern. However, human anthrax infection is primarily a result of direct or indirect contact with infected animals or exposure to contaminated animal products.

Bacillus anthracis, the causative agent of anthrax, is believed to induce disease and death in humans in an endotoxic shocklike manner. A comprehensive study of the effects of anthrax lethal toxin in mice by Stephen Leppla and colleagues at the National Institutes of Health demonstrated that toxin-induced death does not result from septic shock mediated by cytokine release as previously thought, but via hypoxia-induced liver failure. The study strongly suggests that the therapies developed for the treatment of cytokine-mediated septic shock will not be appropriate for the treatment of anthrax.

In an accompanying commentary, Alice Prince from Columbia University College of Physicians and Surgeons in New York states that "this analysis of the pathological effects of the B. anthracis lethal toxin should help focus future studies of optimal therapy for patients exposed to this organism. These results make clear that anthrax patients exhibit a unique pathophysiology and should not be considered to have generic shock analogous to Gram-negative sepsis". Prince continues "exactly how the lethal factor produces such profound tissue hypoxia, what metabolic processes are affected in the liver and elsewhere, and how these effects may be blocked will require further studies".


'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
2-Sep-2003


Page: 1

Related biology news :

1. Columbia research to examine gene influence on severity of peridontal disease, therapy response
2. Protective gene may enhance vaccine responses
3. Activated signaling pathway may predict lung cancer patients response to gefitinib
4. Duke study disputes idea that trees can relocate quickly in response to climate change
5. Researchers develop better understanding of immune response to viral infection
6. Molecular motor shuttles key protein in response to light
7. Triple-vaccine strategy stimulates strong HIV-specific immune response in monkeys
8. Genetic basis for individual variations in the response to stress
9. Drunken worms reveal a genetic basis of alcohol response
10. Researchers identify genetic markers to predict response to chemotherapy for colorectal cancer
11. With fat, women have a more visceral response

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/4/2019)... ... ... Mount Sinai researchers have discovered how the enzyme DNA polymerase delta works to ... a study published in Nature Structural & Molecular Biology, the team also reported how ... diseases. , “DNA polymerase delta serves as the duplicating machine for the millions to ...
(Date:9/30/2019)... ... September 30, 2019 , ... USDM Life Sciences ... life science organizations to accelerate innovation and maximize productivity, announces that David Blewitt ... What: Just 30 days to 21 CFR Part 11 compliance with Box, When: ...
(Date:9/25/2019)... ... September 25, 2019 , ... Modality Solutions, a ... on Inc. Magazine’s annual Inc. 5000 list, the most prestigious ranking of the ... Based on this growth, the Houston-based firm also ranked No. 47 in its ...
Breaking Biology News(10 mins):
(Date:10/3/2019)... BOSTON (PRWEB) , ... October 03, 2019 , ... Yesterday, ... 2-3, Asymmetrex founder and director, James L. Sherley, M.D., Ph.D., discussed important ... To an attendee audience including both developers and suppliers of clinical trials, in ...
(Date:9/24/2019)... ... 2019 , ... Personalized Stem Cells, Inc (“PSC”), ... clinical trial sites and physician investigators. The clinical trial sites are now ... Clinical trial sites are currently located in San Diego and Los Angeles California, ...
(Date:9/17/2019)... ... September 17, 2019 , ... Tucker, a Labrador retriever, was ... months old, Tucker was limping and lame on his right hip and elbow. At ... it was called “the worst case the vet had seen.” He was prescribed pain ...
(Date:9/17/2019)... ... September 16, 2019 , ... MyBioGate Global Healthcare Innovation ... Biotech Week Boston, a forum organized by MyBioGate, Inc. and CUBIO Innovation Center ... a careful process of evaluation, twelve companies out of over 200 applications were ...
Breaking Biology Technology:
Cached News: